Orelabrutinib versus ibrutinib for patients with refractory/relapsed primary central nervous system lymphoma: An efficacy and safety analysis
Article in Medicine (July 2023)
The most recent citing publications are shown below. View all 32 publications that cite this research output on Dimensions.
Article in Medicine (July 2023)
Article in Journal of Clinical Pharmacy and Therapeutics (October 2022)
Article in Frontiers in Oncology (June 2022)